The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study
Abstract
OBJECTIVE: To assess procedural safety and glycemic indices at 6 months in a first-in-human study of duodenal mucosal resurfacing (DMR), a novel, minimally invasive, upper endoscopic procedure involving hydrothermal ablation of the duodenal mucosa, in patients with type 2 diabetes and HbA1c ≥7.5% (58 mmol/mol) on one or more oral antidiabetic agents. RESEARCH DESIGN AND METHODS: Using novel balloon catheters, DMR was conducted on varying lengths of duodenum in anesthetized patients at a single medical center. RESULTS: A total of 39 patients with type 2 diabetes (screening HbA1c 9.5% [80 mmol/mol]; BMI 31 kg/m2) were treated and included in the interim efficacy analysis: 28 had a long duodenal segment ablated (LS; ∼9.3 cm treated) and 11 had a short segment ablated (SS; ∼3.4 cm treated). Overall, DMR was well tolerated with minimal gastrointestinal symptoms postprocedure. Three patients experienced duodenal stenosis treated successfully by balloon dilation. HbA1c was reduced by 1.2% at 6 months in the full cohort (P < 0.001). More potent glycemic effects were observed among the LS cohort, who experienced a 2.5% reduction in mean HbA1c at 3 months postprocedure vs. 1.2% in the SS group (P < 0.05) and a 1.4% reduction at 6 months vs. 0.7% in the SS group (P = 0.3). This occurred despite net medication reductions in the LS cohort between 0 and 6 months. Among LS patients with a screening HbA1c of 7.5–10% (58–86 mmol/mol) and on stable antidiabetic medications postprocedure, HbA1c was reduced by 1.8% at 6 months (P < 0.01). CONCLUSIONS: Single-procedure DMR elicits a clinically significant improvement in hyperglycemia in patients with type 2 diabetes in the short-term, with acceptable safety and tolerability. Long-term safety, efficacy, and durability and possible mechanisms of action require further investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The intragastric balloon and transpyloric shuttle trials included some persons with T2D, but numbers were inadequate to assess safety and efficacy in those with T2D.787–789”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [787]
In the citing paper
“Some endoscopic and orally delivered devices have been approved by the FDA for treatment of obesity, including hydrogel capsules,786 intragastric balloon systems,787–788 a transpyloric shuttle that blocks gastric emptying,789 and gastric aspiration therapy that evacuates partial gastric contents following meals via a variation of a percutaneous endoscopic gastrostomy tube.790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [787]
In the citing paper
“While weight loss following DMR is modest (~2.5 kg at six months), significant metabolic benefits have been reported.”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [92]
In the citing paper
“Improvements in glycemic control, including a 1.2% reduction in HbA1c at six months, have been observed, particularly following long-segment ablation [92].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [92]
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“Despite a wide choice of pharmacological interventions, many patients do not achieve adequate control of hyperglycemia (1).”
BackgroundRubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G. M. M., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0236 · Cited by 1,008
Self-citationRubino, F., Forgione, A., Cummings, D. E., Vix, M., Gnuli, D., Mingrone, G., Castagneto, M., & Marescaux, J. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000224726.61448.1b · Cited by 928
Self-citationRubino, F., & Marescaux, J. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000102989.54824.fc · Cited by 617
Self-citationHuman duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Theodorakis, M. J., Carlson, O., Michopoulos, S., Doyle, M. E., Juhaszova, M., Petraki, K., & Egan, J. M. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00326.2004 · Cited by 396 · cited 1×
“Duodenal biopsy from humans with diabetes also shows hypertrophy, thickening, and an overgrowth of entero-endocrine cell types (22).”
BackgroundLaferrère, B., Reilly, D., Arias, S., Swerdlow, N., Gorroochurn, P., Bawa, B., Bose, M., Teixeira, J., Stevens, R. D., Wenner, B. R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002043 · Cited by 384
Jacobsen, S. H., Olesen, S. C., Dirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Kielgast, U., Worm, D., Almdal, T., Naver, L. S., Hvolris, L. E., et al. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0621-4 · Cited by 342
Jørgensen, N. B., Jacobsen, S. H., Dirksen, C., Bojsen-Møller, K. N., Naver, L., Hvolris, L., Clausen, T. R., Wulff, B. S., Worm, D., Lindqvist Hansen, D., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2012 · Cited by 313
Bojsen-Møller, K. N., Dirksen, C., Jørgensen, N. B., Jacobsen, S. H., Serup, A. K., Albers, P. H., Hansen, D. L., Worm, D., Naver, L., Kristiansen, V. B., et al. (2014) · Diabetes · doi:10.2337/db13-1307 · Cited by 254
Breen, D. M., Rasmussen, B. A., Kokorovic, A., Wang, R., Cheung, G. W. C., & Lam, T. K. T. (2012) · Nature Medicine · doi:10.1038/nm.2745 · Cited by 209 · cited 1×
“This suggests a potential effect on hepatic glucose production, possibly through an insulin-sensitizing mechanism, in line with previous observations in duodenal-jejunal bypass (17) and Roux-en-Y gastric bypass surgery (18–20).”
ResultCamastra, S., Gastaldelli, A., Mari, A., Bonuccelli, S., Scartabelli, G., Frascerra, S., Baldi, S., Nannipieri, M., Rebelos, E., Anselmino, M., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2193-6 · Cited by 196 · cited 1×
“In the LS cohort, DMR exerted improvements in glycemia as early as 1–2 weeks postprocedure, similar to the prompt effects seen after bariatric surgery and suggesting the possibility of similar mechanisms of action (9,16).”
BackgroundMedication Nonadherence in Diabetes
Egede, L. E., Gebregziabher, M., Dismuke, C. E., Lynch, C. P., Axon, R. N., Zhao, Y., & Mauldin, P. D. (2012) · Diabetes Care · doi:10.2337/dc12-0572 · Cited by 195
Ferrannini, E., & Mingrone, G. (2009) · Diabetes Care · doi:10.2337/dc08-1762 · Cited by 194 · cited 1×
“, the endoluminal sleeve) that prevent contact between duodenal mucosa, bile, and nutrients improve insulin sensitivity (11) and b-cell function (12).”
BackgroundSelf-citationMetabolic surgery: the role of the gastrointestinal tract in diabetes mellitus
Rubino, F., R'bibo, S. L., del Genio, F., Mazumdar, M., & McGraw, T. E. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.268 · Cited by 173 · cited 1×
“More specifically, exclusion of nutrient contact from an abnormal duodenal surface in type2diabetesmayelicit beneficial downstream effects on metabolism, perhaps through the reduction of putative anti-incretin mechanisms (15).”
BackgroundSelf-citationGanz, R. A., Utley, D. S., Stern, R. A., Jackson, J., Batts, K. P., & Termin, P. (2004) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(04)02220-5 · Cited by 171 · cited 1×
“The DMR procedure is analogous to the commonly performed radiofrequency ablation of the esophagus, where ablation and subsequent healing of esophageal mucosa is used to treat Barrett esophagus and esophageal dysplasia (34,35).”
MethodEndoscopic Duodenal–Jejunal Bypass Liner Rapidly Improves Type 2 Diabetes
de Jonge, C., Rensen, S. S., Verdam, F. J., Vincent, R. P., Bloom, S. R., Buurman, W. A., le Roux, C. W., Schaper, N. C., Bouvy, N. D., & Greve, J. W. M. (2013) · Obesity Surgery · doi:10.1007/s11695-013-0921-3 · Cited by 160
Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device
Dunkin, B. J., Martínez‐López, J., Bejarano, P. A., Smith, C. D., Chang, K. J., Livingstone, A. S., & Melvin, W. S. (2005) · Surgical Endoscopy · doi:10.1007/s00464-005-8279-9 · Cited by 145 · cited 1×
“The DMR procedure is analogous to the commonly performed radiofrequency ablation of the esophagus, where ablation and subsequent healing of esophageal mucosa is used to treat Barrett esophagus and esophageal dysplasia (34,35).”
MethodUmeda, L. M., Silva, E. A., Carneiro, G., Arasaki, C. H., Geloneze, B., & Zanella, M. T. (2011) · Obesity Surgery · doi:10.1007/s11695-011-0412-3 · Cited by 137
Irwin, N., & Flatt, P. R. (2009) · Diabetologia · doi:10.1007/s00125-009-1422-8 · Cited by 133 · cited 1×
“Moreover, studies in animals and humans show that duodenal exclusion ameliorates the metabolic disturbance (9,29,30) of type 2 diabetes, and in humans and rats, an intestinal device that prevents nutrient contact with the duodenal mucosa also leads to improvement in metabolic measures (31–33).”
BackgroundNguyen, N. Q., Debreceni, T. L., Bambrick, J. E., Chia, B., Wishart, J. M., Deane, A. M., Rayner, C. K., Horowitz, M., & Young, R. L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3144 · Cited by 129 · cited 1×
“The duodenal mucosa becomes abnormal with high fat/hexose feeding (10,21–25), which in turn disturbs local nutrient absorption (26) and neuronal and hormonal signaling (24,25,27).”
BackgroundKindel, T. L., Yoder, S. M., Seeley, R. J., D’Alessio, D. A., & Tso, P. (2009) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-009-0912-9 · Cited by 122
Dirksen, C., Hansen, D. L., Madsbad, S., Hvolris, L., Naver, L., Holst, J. J., & Worm, D. (2009) · Diabetes Care · doi:10.2337/dc09-1374 · Cited by 117 · cited 1×
“Further, in a rat model and in patients with type 2 diabetes who have undergone Roux-en-Y gastric bypass surgery, the improvement of glucose tolerance is quickly reversed when the bypassed duodenum is acutely re-exposed to nutrients introduced via gastrostomy in the remnant stomach (13,14).”
BackgroundBailey, C. J., Flatt, P. R., Kwasowski, P., Powell, C. J., & Marks, V. (1986) · European Journal of Endocrinology · doi:10.1530/acta.0.1120224 · Cited by 116 · cited 1×
“This appears to also involve the overgrowth of certain mucosal cell types, including the K cell (10,23), which is recognized for its glucoregulatory role in secreting the incretin hormoneGIP.”
BackgroundGniuli, D., Calcagno, A., Libera, L. D., Calvani, R., Leccesi, L., Caristo, M. E., Vettor, R., Castagneto, M., Ghirlanda, G., & Mingrone, G. (2010) · Diabetologia · doi:10.1007/s00125-010-1830-9 · Cited by 99 · cited 2×
“Observations in animal models and humans reveal that the duodenal mucosa exhibits abnormal hypertrophy and endocrine hyperplasia in the presence of diabetes (10).”
BackgroundSelf-citationAdachi, T., Mori, C., Sakurai, K., Shihara, N., Tsuda, K., & Yasuda, K. (2003) · Endocrine Journal · doi:10.1507/endocrj.50.271 · Cited by 89
Klein, S., Fabbrini, E., Patterson, B. W., Polonsky, K. S., Schiavon, C. A., Correa, J. L., Salles, J. E. N., WAJCHENBERG, B. L., & COHEN, R. V. (2012) · Obesity · doi:10.1038/oby.2011.377 · Cited by 69 · cited 1×
“, the endoluminal sleeve) that prevent contact between duodenal mucosa, bile, and nutrients improve insulin sensitivity (11) and b-cell function (12).”
BackgroundSalinari, S., le Roux, C. W., BERTUZZI, A., Rubino, F., & Mingrone, G. (2013) · Diabetes · doi:10.2337/db13-0856 · Cited by 61
Self-citationDuodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia
Habegger, K. M., Al–Massadi, O., Heppner, K. M., Myronovych, A., Holland, J., Berger, J., Yi, C., Gao, Y., Lehti, M., Ottaway, N., et al. (2013) · Gut · doi:10.1136/gutjnl-2013-304583 · Cited by 59 · cited 1×
“Moreover, studies in animals and humans show that duodenal exclusion ameliorates the metabolic disturbance (9,29,30) of type 2 diabetes, and in humans and rats, an intestinal device that prevents nutrient contact with the duodenal mucosa also leads to improvement in metabolic measures (31–33).”
BackgroundModifications of gastric inhibitory polypeptide (GIP) secretion in man by a high-fat diet
Morgan, L., Hampton, S., Tredger, J. A., Cramb, R., & Marks, V. (1988) · British Journal Of Nutrition · doi:10.1079/bjn19880046 · Cited by 58 · cited 1×
“The duodenal mucosa becomes abnormal with high fat/hexose feeding (10,21–25), which in turn disturbs local nutrient absorption (26) and neuronal and hormonal signaling (24,25,27).”
BackgroundSalinari, S., Debard, C., BERTUZZI, A., Durand, C., Zimmet, P., Vidal, H., & Mingrone, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056258 · Cited by 55 · cited 1×
“In addition, an as yet unidentified factor isolated from proximal intestinal cells may directly impact systemic insulin sensitivity, as myocytes become insulin resistant when exposed in vitro to proteins produced by duodenal/jejunal mucosa from subjects with diabetes (28).”
BackgroundSelf-citationZervos, E. E., Agle, S. C., Warren, A. J., Lang, C. G., Fitzgerald, T. L., Dar, M. S., Rotondo, M. F., & Pories, W. J. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2009.12.025 · Cited by 41
Shimizu, H., Eldar, S. M., Heneghan, H., Schauer, P. R., Kirwan, J. P., & Brethauer, S. A. (2013) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2013.01.021 · Cited by 31 · cited 1×
“Further, in a rat model and in patients with type 2 diabetes who have undergone Roux-en-Y gastric bypass surgery, the improvement of glucose tolerance is quickly reversed when the bypassed duodenum is acutely re-exposed to nutrients introduced via gastrostomy in the remnant stomach (13,14).”
BackgroundMuñoz, R., Carmody, J. S., Stylopoulos, N., Davis, P. J., & Kaplan, L. M. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00262.2012 · Cited by 26
Self-citationPonter, A. A. A., Salter, D. N., Morgan, L., & Flatt, P. R. (1991) · British Journal Of Nutrition · doi:10.1079/bjn19910024 · Cited by 25 · cited 1×
“The duodenal mucosa becomes abnormal with high fat/hexose feeding (10,21–25), which in turn disturbs local nutrient absorption (26) and neuronal and hormonal signaling (24,25,27).”
BackgroundFlatt, P. R., Bailey, C. J., Kwasowski, P., & Swanston-Flatt, S. K. (1990) · PubMed · Cited by 8
Cited by
The science of obesity management: an endocrine society scientific statement
Bray, G. A., Heisel, W. E., Afshin, A., Jensen, M. D., Dietz, W. H., Long, M., Kushner, R. F., Daniels, S. R., Wadden, T. A., Tsai, A. G., et al. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00253 · Cited by 812
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., & Xu, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1161521 · Cited by 799
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.10.025 · Cited by 608
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0406 · Cited by 510
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Metadata
- Authors
- Rajagopalan, H., Cherrington, A. D., Thompson, C. C., Kaplan, L. M., Rubino, F., Mingrone, G., Becerra, P., Rodriguez, P., Vignolo, P., Caplan, J., Rodriguez, L., & Galvao Neto, M. P.
- Affiliations
- Fractyl (United States) (US)
- Vanderbilt University Medical Center (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
- King's College London (GB)
- Catholic University of Rome, Rome, Italy
- CCO Clinical Center for Diabetes, Obesity and Reflux, Santiago, Chile
- Gastro Obeso Center, São Paulo, Brazil
- Corresponding author
- Rajagopalan, Harith
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-08-12
- Volume
- 39
- Issue
- 12
- Pages
- 2254-2261
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2514895276
- Cited by
- 216
- References
- 35
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 17 · 2023: 14 · 2022: 17 · 2021: 25 · 2020: 34 · 2019: 24 · 2018: 20 · 2017: 32 · 2016: 2
- FWCI
- 26.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Fractyl Laboratories, Inc
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- duodenal mucosal resurfacing, type 2 diabetes, HbA1c reduction, glycemic control, balloon catheter, duodenal stenosis, antidiabetic medication reduction, procedural safety, first-in-human study
- MeSH terms
- Adult, Aged, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Duodenum, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Intestinal Mucosa, Male, Middle Aged, Pilot Projects, Endoscopy, Gastrointestinal, Bariatric Surgery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.